RCKT stock forecast, quote, news & analysis
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company... Show more
Why Rocket Pharmaceuticals (RCKT) Is Down -25% in the Last 30 Days
Key Takeaways
- RCKT stock declined approximately -25% over the past 30 days, from around $5.01 on February 27 to $3.77 on March 27, amid high volatility peaking at $5.30 before a sharp drop.
- Over the past quarter, the stock rose about +10%, advancing from $3.42 in late December 2025 to the recent close, driven by pipeline progress.
- FDA accelerated approval of KRESLADI gene therapy on March 27 triggered initial optimism but led to a -19.6% plunge, reflecting profit-taking and concerns over commercialization.
- Q4 2025 earnings beat estimates with narrower loss, bolstering sentiment earlier in the period.
- Analyst upgrades and positive ratings on gene therapy platform provided support, though dilution fears from $100M ATM offering weighed in.
- Biotech sector volatility and macroeconomic pressures contributed to range-bound trading.
Rocket Pharmaceuticals (RCKT) Company Overview and Market Position
Rocket Pharmaceuticals, Inc. (RCKT) is a late-stage biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. Its core business model centers on lentiviral vector-based platforms to address genetic disorders like leukocyte adhesion deficiency-I (LAD-I) and Danon disease. Operating in the competitive gene therapy segment, Rocket differentiates through its pipeline of AAV and LVV candidates targeting unmet needs in immunology and cardiology. Strong fundamentals, including FDA-validated manufacturing and clinical data, underpin recent stock behavior, as regulatory milestones directly influence investor sentiment in this high-risk, high-reward industry.
Rocket Pharmaceuticals (RCKT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, RCKT stock fell -25%, closing at $3.77 on March 27 from $5.01 around February 27. The movement was volatile, with a peak of $5.30 on March 10 followed by a steady decline and a -19.6% single-day drop on March 27 amid massive volume of over 23 million shares.
For the quarter, shares gained +10%, rising from $3.42 in late December 2025. The trend featured an early recovery from lows near $3.00 in early February, building to mid-March highs before recent pullback, reflecting trend-driven gains interrupted by event-based selling.
What Drove RCKT Stock Price in the Last 30 Days
The 30-day downturn stemmed primarily from profit-taking after a rally to $5.30, fueled by anticipation of the March 27 FDA PDUFA for KRESLADI. Despite accelerated approval for pediatric severe LAD-I—the first gene therapy for this condition—shares plunged -19.6%, as investors sold into the news amid concerns over near-term revenue ramp-up for the rare disease therapy.
Earlier, Q4 2025 earnings on February 27 showed a narrower-than-expected -$0.38 EPS loss versus -$0.42 consensus, lifting shares +10.6% that day. Analyst upgrades, including Cantor Fitzgerald to $10 and Leerink to $11 post-approval, offered counterbalance but couldn't stem dilution fears from a $100M at-the-market offering announced March 10. Sector sentiment and biotech volatility exacerbated the range-bound action.
What Drove RCKT Stock Performance Over the Last Quarter
The quarterly +10% gain reflected sustained pipeline momentum, with BLA resubmission acceptance for KRESLADI in October 2025 de-risking the program ahead of PDUFA. Broader industry tailwinds in gene therapy, including positive long-term data from Danon disease trials published in NEJM, supported recovery from February lows near $3.00.
Macroeconomic factors like interest rate stability aided biotech funding, while institutional accumulation amid undervaluation—average analyst target $8.50—drove flows. A $182.5M public offering in December 2025 extended runway, though it pressured sentiment initially. Cumulative impact came from regulatory progress outweighing cash burn in a challenging biotech environment.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from hundreds available, scanning thousands of tickers across strategies like swing trading, scalping, and long-term trends. These curated bots highlight real-time performance metrics, win rates, and risk-adjusted returns, helping traders identify relevant tools for volatile assets like biotech stocks. Updated dynamically, the section features bots excelling in recent market conditions, varying by timeframe from intraday to multi-month holds. Explore Tickeron’s AI robots to enhance your stock analysis and automate trading decisions.
RCKT Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor KRESLADI launch progress, including rare pediatric priority review voucher monetization potentially worth $100-200M non-dilutively. Upcoming Phase 2 updates for RP-A501 in Danon disease and BAG3 cardiomyopathy data in H1 2026 could catalyze sentiment. Macro trends in biotech funding, FDA interactions on manufacturing, and Q1 earnings remain key. Risks include commercialization hurdles for rare diseases, dilution from ATM sales, and sector-wide regulation shifts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
RCKT's RSI Indicator climbs out of oversold territory
The RSI Oscillator for RCKT moved out of oversold territory on June 12, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 45 similar instances when the indicator left oversold territory. In of the 45 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 17, 2026. You may want to consider a long position or call options on RCKT as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for RCKT just turned positive on June 15, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
RCKT moved above its 50-day moving average on June 18, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for RCKT moved below the 200-day moving average on June 01, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RCKT broke above its upper Bollinger Band on June 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RCKT entered a downward trend on June 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.537) is normal, around the industry mean (20.056). P/E Ratio (0.000) is within average values for comparable stocks, (35.868). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). RCKT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (361.304).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RCKT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of gene therapy services
Industry Biotechnology